Compare Heartflow Inc. Common Stock (HTFL) vs Vaxcyte Inc. Common Stock (PCVX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heartflow Inc. Common Stock vs Vaxcyte Inc. Common Stock — how do they compare? Heartflow Inc. Common Stock trades at $49.44 (market cap $4.38B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Vaxcyte Inc. Common Stock is far larger — about 2.4× Heartflow Inc. Common Stock's market cap, and Heartflow Inc. Common Stock is trading nearer its 52-week high, Vaxcyte Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heartflow Inc. Common Stock for 0 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| HTFL | PCVX | |
|---|---|---|
Market Cap | $4.38B | $10.51B |
Volume | 1,454,420 | 2,644,694 |
Sector | Health | Health |
52-Week High | $52.21 | $73.82 |
52-Week Low | $20.49 | $40.32 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $4.24B | $9.14B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heartflow Inc. Common Stock
HeartFlow, Inc. develops AI-powered software that analyzes coronary CT angiography scans to build personalized 3D heart models for coronary artery disease diagnosis, including its FFRct Analysis, Plaque Analysis, and Roadmap Analysis tools.
Read more on HTFL →About Vaxcyte Inc. Common Stock
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →
